Mass spectrometry-based assay for the molecular diagnosis of glioma : Concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status by C. Pesenti et al.
Oncotarget57134www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 34), pp: 57134-57148
Mass spectrometry-based assay for the molecular diagnosis 
of glioma: concomitant detection of chromosome 1p/19q 
codeletion, and IDH1, IDH2, and TERT mutation status
Chiara Pesenti1,2, Leda Paganini1,2, Laura Fontana1, Emanuela Veniani2, Letterio 
Runza2, Stefano Ferrero2,3, Silvano Bosari1,2, Maura Menghi4, Giovanni Marfia5,6, 
Manuela Caroli6, Rosamaria Silipigni7, Silvana Guerneri7, Silvia Tabano1 and 
Monica Miozzo1,2
1Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
2Division of Pathology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
3Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Milan, Italy
4Diatech Pharmacogenetics, Jesi, Italy
5Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Fondazione IRCCS Ca’ Granda, Ospedale 
Maggiore Policlinico, Milan, Italy
6Neurosurgery Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
7Laboratory of Medical Genetics, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Correspondence to: Silvia Tabano, email: silvia.tabano@unimi.it
Keywords: glioma, 1p/19q LOH, massARRAY, IDH, TERT
Received: March 13, 2017    Accepted: June 19, 2017    Published: July 08, 2017
Copyright: Pesenti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
The World Health Organization recently revised the diagnosis of glioma, to 
integrate molecular parameters, including IDH mutations and codeletion (loss of 
heterozygosity; LOH) of chromosome arms 1p/19q, into the definitions of adult glioma 
histological subtypes. Mutations in the TERT promoter may also be useful for glioma 
diagnosis and prognosis. The integration of molecular markers into routine diagnosis 
requires their rapid and reliable assessment. We propose a MassARRAY (MS)-based 
test that can identify 1p/19q codeletion using quantitative SNP genotyping and, 
simultaneously, characterize hotspot mutations in the IDH1, IDH2, and TERT genes 
in tumor DNA. We determined the reliability of the MS approach testing 50 gliomas 
and comparing the MS results with those obtained by standard methods, such as short 
tandem repeat genotyping, array comparative genomic hybridization (array-CGH) 
and Fluorescence In Situ Hybridization (FISH) for 1p/19q codeletion and Sanger 
sequencing for hotspots mutations. The results indicate that MS is suitable for the 
accurate, rapid, and cost-effective evaluation of chromosome deletions combined 
with hotspot mutation detection. This MS approach could be similarly exploited in 
evaluation of LOH in other situations of clinical and/or research importance.
INTRODUCTION
Diffuse gliomas are the most common brain tumor, 
accounting for 27% of all brain neoplasms and 80% of 
malignant tumors [1]. Until last year, diffuse gliomas 
were classified on the basis of histological criteria 
and 2007 World Health Organization (WHO) grading 
[2]. The increasing and extensive characterization 
of the genomic landscape of gliomas prompted the 
identification of genetic and epigenetic markers useful 
for tumor molecular classification; in the future, these 
molecular signatures could also represent actionable 
targets in gliomas, as is already the case for other 
cancers [3–5]. 
                                                       Research Paper
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At the beginning of 2016, the WHO Classification 
of Tumors of the Central Nervous System (CNS) (2016 
CNS WHO) revised the diagnostic guidelines for gliomas, 
to include molecular markers and create a novel concept of 
diagnosis, termed “integrated” diagnosis, characterized by 
the concomitant evaluation of phenotypic and genotypic 
parameters [6]. This new integrated diagnostic process 
not only aims to achieve greater objectivity, but also to 
improve patient management. The 2016 CNS WHO 
criteria state that, for a complete diagnosis of the types 
of adult glioma, analysis for specific mutations of the two 
genes, IDH1 and IDH2 (IDH), which encode isocitrate 
dehydrogenase 1 and 2, respectively, and of chromosome 
1p/19q codeletion status, is essential.
Mutations of IDH1 (codon 132) or IDH2 (codon 
172) allow discrimination between two classes of 
glioblastoma (GBM), IDH-wildtype and IDH-mutant, 
with differing genomic and epigenomic landscapes and 
prognoses [5, 7, 8]. Moreover, IDH mutations are almost 
invariably present in low grade gliomas (LGGs), including 
oligodendroglioma (ODG) and astrocytoma (AC) [7, 9]. 
IDH mutations are an early event in glioma tumorigenesis 
[5], and several mechanisms have been proposed to 
explain their role in neoplastic transformation. Mutant 
IDH enzymes acquire neomorphic activity and produce 
an oncometabolite, 2-HG, which is able to modify the 
epigenetic profile of cells, leading to the establishment 
of the CpG island methylator phenotype (G-CIMP). 
The production of 2-HG stimulates cell proliferation 
by reducing levels of the hypoxia-inducible factors. 
Moreover, IDH mutations promote tumorigenesis by 
decreasing intracellular levels of NADPH, which also has 
the effect of increasing the sensitivity of tumor cells to 
cytotoxic therapies, accounting for the positive prognostic 
value of this marker (see [10] for a review). 
Once the IDH mutation status has been defined, the 
histological type of LGGs can be determined by evaluation 
of 1p/19q status. Codeletion of the chromosome arms 
1p and 19q (1p/19q loss of heterozygosity; LOH) is the 
result of the unbalanced translocation [t(1;19)(q10;p10)] 
and enables discrimination between ODG and AC. Both 
of these LGGs are characterized by IDH mutations; 
however, only ODGs exhibit 1p/19q codeletion [6, 9]. 
Furthermore, the presence of 1p/19q LOH in ODGs is 
positively correlated with sensitivity to radiotherapy and 
chemotherapy using alkylating agents [11].
In addition to IDH and 1p/19q status, two mutations 
in the promoter region of the telomerase reverse 
transcriptase (TERT) gene are frequently identified in 
various types of cancer [12, 13], including glioma [14, 15]. 
These single nucleotide substitutions occur in a mutually 
exclusive manner in two hotspot positions upstream of the 
ATG start site: c.-124G>A and c.-146G>A (also termed 
C228T and C250T, respectively). The mutations generate 
a consensus binding site for the E-twenty-six transcription 
factor, which upregulates TERT expression and thus 
induces the maintenance of telomere length and tumor 
proliferation [16–19]. 
TERT promoter mutations are found in more 
than 70% of GBMs, in particular in the IDH-wildtype 
subgroup, and in almost all ODGs (nearly 95%) [6]. 
These mutations occur less frequently in ACs, which 
usually have mutations in the alpha thalassemia/mental 
retardation syndrome X-linked (ATRX) gene, another locus 
involved in telomere lengthening [20]. The presence of 
TERT mutations is also important for glioma prognosis, 
since gliomas (in particular LGGs) with concomitant IDH 
and TERT mutations are associated with better prognosis, 
while patients with IDH-wildtype and TERT mutated 
GBMs have poorer prognoses. 
The absence of MGMT promoter methylation is an 
additional negative prognostic factor in TERT mutated 
GBM [8, 15, 21–24], and assessment of MGMT promoter 
methylation status assists in better defining prognosis for 
patients with gliomas, due to the role of this feature as a 
predictive marker of therapeutic efficacy [25].
Figure 1 summarizes the molecular diagnostic 
flowchart proposed by the 2016 CNS WHO, comprising 
analysis of the markers described above, and suggests the 
evaluation of additional genes, including ATRX and TP53 
mutations [4, 20], for profiling of ACs, TERT mutations 
for ODGs and GBMs, and MGMT promoter methylation 
for GBMs.
Together, these molecular markers allow the 
stratification of glioma patients in terms of prognosis 
and response to treatments [20, 26, 27], highlighting the 
importance of early molecular profiling of gliomas for a 
more precise patient management.
The presence of 1p/19q LOH is routinely assessed 
by FISH or genotyping of short tandem repeats (STRs), 
while IDH and TERT mutations are usually investigated 
by sequencing or real-time PCR. The use of multiple 
techniques for diagnostic purposes is laborious and time-
consuming. Conversely, next generation sequencing 
(NGS) approaches [28–30] allow the simultaneous 
detection of markers; however, the technique is very 
expensive for use in medium-sized laboratories where, in 
general, only a few cases will be analyzed simultaneously. 
To overcome these limitations, we propose the MS system 
as a feasible high-throughput technology to simultaneously 
define the presence of 1p/19q LOH and hotspot mutations 
in IDH1, IDH2, and TERT. 
MS technology uses a matrix-assisted laser 
desorption ionization time-of-flight (MALDI-TOF) mass-
spectrometry platform to perform multiplex genotyping 
with high accuracy, even where only small amounts of 
poor-quality template material, such as DNA obtained 
from formalin-fixed paraffin-embedded (FFPE) tissue 
samples, are available [31]. The technique has already 
been introduced for routine diagnostics as a fast, reliable, 
and cost-effective approach, with specific CE marked 
in vitro diagnostic tests in Europe for the molecular 
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characterization of colon and lung cancer [32]. Two 
previous reports [33, 34] investigated colon and lung 
cancers and demonstrated that MS can be exploited for the 
identification of chromosome deletions. In particular, van 
Puijgenbroek et al. [33] analyzed only one SNP in colon 
cancers and Tai et al. [34] evaluated a panel of SNPs, but 
without a quantitative approach to define the presence/
absence of the deletions. Nevertheless, deletion analysis 
by MS has not been previously applied in molecular 
diagnosis of cancers, and CE marked in vitro diagnostic 
tests using this method are not currently available to 
analyze LOH, either alone or together with cancer hotspot 
mutations. 
To develop an accurate test for 1p/19q LOH by MS, 
we quantitatively genotyped a panel of highly polymorphic 
biallelic single nucleotide polymorphisms (SNPs) evenly 
distributed along chromosomes 1p and 19q. We applied 
the proposed technique to 50 gliomas and compared the 
results of MS for 1p/19q LOH with those obtained by the 
standard methods, STR genotyping, array-CGH and FISH. 
In addition, we genotyped by MS IDH1 codon 132, IDH2 
codon 172, TERT c.-124C>T and c.-146C>T promoter 
mutations, validating the results by Sanger sequencing. 
The results described here demonstrate that the MS 
test accurately combines the evaluation of IDH and TERT 
mutations with that of 1p/19q LOH, in accordance with 
the recent WHO guidelines. 
RESULTS
MS assay optimization for molecular diagnosis 
of gliomas
The MS assay optimized in our laboratory is able to 
reveal LOH at 1p/19q chromosome arms and the presence 
of hotspot mutations in IDH1, IDH2, and TERT. It was 
optimized and validated by the analysis of 50 glioma 
samples, as detailed below.
For 1p/19q LOH analysis, we applied specific 
criteria to define SNPs as heterozygous and a formula 
to assess LOH, as detailed in Materials and Methods. 
An example of a sample with LOH, in which one of 
the two alleles detected in blood DNA was lost in the 
corresponding tumor DNA, thus significantly modifying 
the allele frequencies and resulting in a value of 0.9 using 
our formula, is presented in Figure 2A. An example of 
Figure 1: Simplified flowchart for the molecular characterization of diffuse gliomas (adapted from 2016 CNS WHO 
[5]). The detection of IDH mutations allows the distinction between primary and secondary GBM in HGGs and is necessary to discriminate 
between the LGGs, astrocytoma, and oligodendroglioma. LGGs with wildtype IDH are very rarely observed and, after the exclusion of 
other possible diagnoses, should be classified as NOS (not otherwise specified). The analysis of 1p/19q LOH is necessary to distinguish 
between oligodendroglioma and astrocytoma. *Other genetic markers characteristic of each type of glioma, not yet required for diagnosis, 
but useful for the molecular characterization of glioma (i.e., TERT, TP53, and ATRX mutations, and MGMT methylation). 
Oncotarget57137www.impactjournals.com/oncotarget
a sample with no LOH, in which the allele signals and 
frequencies from peripheral blood lymphocyte (PBL) and 
tumor DNA were similar and the value calculated using 
the formula was 0.50 (i.e., within the range defined as no 
imbalance; > 0.3 < 0.7), is shown in Figure 2B.
LOH/NO LOH status was defined by the presence 
of at least two informative SNPs per chromosome arm 
with concordant results, one of which was located in a 
centromeric region and the other at a telomeric locus. 
Overall, we found that the average number of informative 
SNPs per sample was about six for both chromosome 
regions. As detailed in Table 1, more than two informative 
SNPs were available in all cases, with the exception of 
cases n. 29 and 36, showing only two informative SNPs on 
19q chromosome arm. As reported in Supplementary Table 
1, heterozygous/informative SNPs were evenly distributed 
along the chromosome arms for each sample, enabling 
discrimination between whole or partial chromosome arm 
deletions. We did not identify any partial deletions of 1p 
and/or 19q in the analyzed population, although the MS 
test has the potential to detect such changes. 
Applying the diagnostic flowchart proposed in 
Figure 1, the molecular characterization by MS supported 
the histological diagnosis. Indeed, 1p/19q LOH is a 
typical feature of ODG and anaplastic ODG and, in our 
population, all 16 ODG samples (Table 1, cases n. 1–16) 
resulted positive for 1p/19q codeletion by MS. Conversely, 
all samples from tumors with other histotypes (AC and 
GBM) did not exhibit 1p/19q LOH or partial deletions of 
these chromosome arms (Table 1 and Figure 3). 
Figure 2: Example of results from gliomas with and without 1p/19q codeletion. Comparison between the allele signals from 
the informative SNP, rs11247639, from blood and tumor DNA from sample 10 and 28. (A) Spectra from a sample positive for LOH. Tumor 
DNA shows evident reduction of the allele 2 signal, compared with blood DNA. (B) Spectra from a sample negative for LOH. No relevant 
differences were observed in allele frequencies between blood and tumor DNA. Black and gray arrows indicate the Allele 1 and 2 peaks, 
respectively, while the unfilled arrows indicate the positions of the extension primers. Allele frequencies calculated by the MS software are 
shown, and the application of the formula confirming the presence or absence of LOH is presented to the right of the plots. The other peak 
present in the spectra represents the allele signal of another SNP of the MS test. The results from other informative SNPs in samples 10 and 
28 were concordant with those from rs11247639 and confirmed the presence of codeletion in case 10 and its absence in case 28.
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As recommended by the 2016 CNS WHO [6], we 
also analyzed samples for mutations at codons 132 and 
172 of IDH1 and IDH2, respectively. In the MS panel, 
24 out of 50 tumors contained one of these mutations. 
The most frequent mutation, found in 20 tumors (13/16 
ODGs, 6/8 ACs, 1/26 GBMs), was IDH1 c.395G>A 
(IDH1 R132H), in accordance with published data [7]; one 
ODG and one AC carried IDH1 c.394C>T (IDH1 R132C) 
mutations, one ODG IDH2 c.514A>T (IDH2 R172W), and 
one ODG IDH2 c.515G>A (IDH2 R172K) (Table 1). The 
frequencies of the wildtype and mutated alleles generated 
using MS were always close to 0.5, implying that 1) the 
mutations were present in almost all analyzed cells; 2) the 
tumor cell content was close to 100%; and 3) the tumors 
were heterozygous for the mutations, in agreement with 
published data [5]. In particular, the average frequency of 
the IDH1 allele encoding the R132H mutation was 0.52% 
± 3% (data not shown). Figure 4A shows a representative 
spectrum from a mutated sample. 
Finally, mutations in TERT promoter were found 
in 38 out of 50 samples. Thirty samples (13/16 ODGs, 
17/26 GBMs) carried the c.-124C>T (TERT G228A) 
mutation and eight (three ODGs and five GBMs) the c.-
146C>T (TERT G250A) mutation (Table 1), supporting 
the predominance of the G228A mutation in glioma [15]. 
Similar to the results of IDH gene analysis, the mutated 
allele of TERT was also highly represented (mean 
frequency: 0.59 ± 0.15); however, the high values of the 
standard deviation found among samples did not allow a 
precise quantification of the mutated allele, probably due 
to bias in the TERT amplification reaction. This could 
be caused by the high enrichment for G/C nucleotides 
in this promoter region, that prevents an optimal DNA 
amplification, as already suggested by another report 
[29]. This issue was not observed with any of the other 
assays performed in this study. Figure 4B illustrates 
representative results from TERT mutated samples. 
Given the histological diagnoses of the analyzed 
samples, the results of our molecular analysis are in line 
with published reports [6]. Indeed, all ODGs were positive 
for both IDH and TERT mutations, seven out of eight ACs 
were IDH-mutant (cases n.18–24), and no AC samples had 
mutations in TERT. Finally, the IDH1 R132H mutation 
was found in only one out of 26 GBM samples (case n 
32); conversely, the TERT mutations, which are frequent 
in GBM, were highly represented in our cases (22 out of 
26 GBMs) (Figure 3). 
MS test validation
To validate the results of the analysis by MS 
(Table 1), we compared them with those obtained using 
reference methods. To test 1p/19q LOH, all 50 tumors 
were investigated by STR genotyping. The results 
obtained by this approach are detailed in Supplementary 
Figure 1A and are completely consistent with those from 
MS assay. Ten cases were also analyzed by FISH (cases 
n. 1, 2, 4, 5 and 7 positive and n. 24, 25, 26, 28 and 30, 
negative for 1p/19q LOH by MS, respectively). The FISH 
results are reported in Supplementary Figure 1B and FISH 
images, representative of 1p/19q codeletion and non-
codeletion status, are depicted in Supplementary Figure 
1C. FISH analyses unequivocally confirmed the MS 
results. Nevertheless, commercial FISH probes, commonly 
used to analyze 1p/19q codeletion, label only the telomeric 
portion of the 1p and 19q; on the contrary, the MS assay 
allows a fine mapping of chromosome deletions because it 
exploits a SNPs panel entirely covering 1p and 19q.
To further verify the efficiency of the MS test, four 
samples (samples nr 9 and 12, positive for LOH, and nr 29 
and 37, negative for LOH) were analyzed by array-CGH. 
The results were concordant with those of MS, confirming 
once more that the MS test correctly detects the codeletion 
of the whole chromosome 1p and 19q arms. 
Finally, Sanger sequencing was exploited to verify 
the hotspot mutations in IDH1, IDH2 and TERT identified 
by MS. The sequencing analysis confirmed the results 
obtained by MS assay in all the investigated cases (marked 
by an asterisk in Table 1). Figures 4C and 4D displays 
the electropherograms of the respective MS spectra of two 
tumors (cases n. 4 and 37) with IDH1 R132H (Figure 4A) 
and TERT G228A (Figure 4B).
DISCUSSION
The revision of the WHO classification of brain 
tumors integrated molecular with histological parameters 
for their diagnosis and made the analysis of genetic 
markers mandatory. Using MS technology, we propose 
a novel, reliable, and cost-effective test that combines 
analyses of the diagnostic markers 1p/19q LOH and IDH 
mutations, required by the 2016 CNS WHO, together with 
the detection of TERT promoter mutations, relevant to 
patient prognosis. 
The 1p/19q LOH assay described in this paper 
genotypes 27 biallelic SNPs, carefully selected based on 
their frequencies in the general population and uniformly 
located across the entire spans of the chromosome 1p 
and 19q arms. The distribution of these SNPs enables 
discrimination between whole and partial chromosome 
deletions, and allows phenotype/genotype correlations, 
as previously reported [11, 35]. This advantage is shared 
by other techniques, including SNP-array and array-
CGH, previously used to study 1p/19q status in gliomas 
[36] and, though these methods do not require a control 
DNA sample from the patient (unlike our technique), 
they are far less reliable when applied to samples with 
low DNA content or quality, such as FFPE samples. In 
routine diagnosis, indeed, application of methods such as 
SNPs or CGH array is challenged by the available amount 
of DNA, as these techniques require large quantities of 
starting material. By contrast, MS can accurately function 
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Table 1: Molecular results obtained by MS assay for 1p/19q LOH, and IDH and TERT mutations 
SAMPLE HYSTOLOGICAL 
TYPE
WHO 
GRADE
LOH
IDH mutations TERT mutations
1p 19q
1 ODG II LOH (3 SNPs) LOH (6 SNPs) IDH1 R132H* TERT G228A*
2 Anaplastic ODG III LOH (7 SNPs) LOH (8 SNPs) IDH1 R132H* TERT G228A*
3 ODG II LOH (10 SNPs) LOH (5 SNPs) IDH1 R132H* TERT G228A
4 Anaplastic ODG III LOH (6 SNPs) LOH (7 SNPs) IDH1 R132H* TERT G228A*
5 ODG II LOH (8 SNPs) LOH (3 SNPs) IDH1 R132C* TERT G228A*
6 ODG II LOH (6 SNPs) LOH (4 SNPs) IDH1 R132H* TERT G228A*
7 ODG II LOH (6 SNPs) LOH (6 SNPs) IDH1 R132H* TERT G228A
8 Anaplastic ODG III LOH (7 SNPs) LOH (7 SNPs) IDH1 R132H* TERT G250A
9 ODG III LOH (3 SNPs) LOH (6 SNPs) IDH2 R172W* TERT G228A
10 ODG II LOH (5 SNPs) LOH (6 SNPs) IDH1 R132H* TERT G228A
11 ODG II LOH (5 SNPs) LOH (4 SNPs) IDH1 R132H* TERT G250A
12 Anaplastic ODG III LOH (9 SNPs) LOH (9 SNPs) IDH2 R172K* TERT G228A
13 ODG II LOH (9 SNPs) LOH (6 SNPs) IDH1 R132H TERT G228A
14 ODG II LOH (7 SNPs) LOH (7 SNPs) IDH1 R132H* TERT G228A*
15 ODG II LOH (8 SNPs) LOH (4 SNPs) IDH1 R132H TERT G228A
16 ODG II LOH (9 SNPs) LOH (7 SNPs) IDH1 R132H* TERT G250A
17 Anaplastic AC III NO LOH (9 SNPs) NO LOH (10 SNPs) WT* WT
18 AC II NO LOH (7 SNPs) NO LOH (5 SNPs) IDH1 R132C WT
19 Anaplastic AC III NO LOH (5 SNPs) NO LOH (6 SNPs) IDH1 R132H* WT
20 AC II NO LOH (8 SNPs) NO LOH (5 SNPs) IDH1 R132H* WT
21 AC II NO LOH (13 SNPs) NO LOH (8 SNPs)
IDH1 R132H* WT
22 AC II NO LOH (6 SNPs) NO LOH (3 SNPs) IDH1 R132H* WT*
23 Anaplastic AC III NO LOH (6 SNPs) NO LOH (3 SNPs) IDH1 R132H* WT
24 AC III NO LOH (8 SNPs) NO LOH (5 SNPs) IDH1 R132H* WT
25 GBM IV NO LOH (6 SNPs) NO LOH (4 SNPs) WT* TERT G250A
26 GBM IV NO LOH (7 SNPs) NO LOH (6 SNPs) WT* TERT G228A
27 GBM IV NO LOH (8 SNPs) NO LOH (8 SNPs) WT* TERT G228A
28 GBM IV NO LOH (5 SNPs) NO LOH (7 SNPs) WT* TERT G250A
29 GBM IV NO LOH (5 SNPs) NO LOH (2 SNPs) WT* TERT G228A
30 GBM IV NO LOH (9 SNPs) NO LOH (7 SNPs) WT* TERT G228A
31 GBM IV NO LOH (4 SNPs) NO LOH (5 SNPs) WT* TERT G228A*
32 GBM IV NO LOH (5 SNPs) NO LOH (6 SNPs) IDH1 R132H* WT
33 GBM IV NO LOH (8 SNPs) NO LOH (4 SNPs) WT* TERT G228A
34 GBM IV NO LOH (8 SNPs) NO LOH (5 SNPs) WT* TERT G250A
35 GBM IV NO LOH (8 SNPs) NO LOH (6 SNPs) WT* WT*
36 GBM IV NO LOH (9 SNPs) NO LOH (2 SNPs) WT* TERT G228A*
37 GBM IV NO LOH (6 SNPs) NO LOH (6 SNPs) WT* TERT G228A*
38 GBM IV NO LOH (7 SNPs) NO LOH (8 SNPs) WT* TERT G250A
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using a very small amount of DNA (approximately 5 ng). 
FISH is an additional technique commonly exploited to 
study chromosome deletions in tumor tissues, because it 
does not require normal counterpart and can be performed 
also when the amount of neoplastic cells is low. Despite 
these advantages, FISH probes usually target solely the 
telomeric region of both chromosome arms, making 
the distinction between whole and partial chromosome 
deletions tricky. Furthermore, FISH is both laborious 
and time-consuming and in some cases the results are not 
conclusive and need PCR-based approach to study the 
LOH in order to complete the analysis [37]. 
A limitation of the MS test is that it requires a 
normal control sample to be applied. As a normal tissue we 
propose the use of patient blood sample, which could be 
easily obtained during the surgery and can be stored until 
39 GBM IV NO LOH (9 SNPs) NO LOH (7 SNPs) WT* TERT G228A*
40 GBM IV NO LOH (7 SNPs) NO LOH (4 SNPs) WT* TERT G250A*
41 GBM IV NO LOH (6 SNPs) NO LOH (6 SNPs) WT* TERT G228A*
42 GBM IV NO LOH (5 SNPs) NO LOH (5 SNPs) WT* TERT G228A
43 GBM IV NO LOH (3 SNPs) NO LOH (7 SNPs) WT* TERT G228A*
44 GBM IV NO LOH (4 SNPs) NO LOH (10 SNPs) WT TERT G228A
45 GBM IV NO LOH (7 SNPs) NO LOH (6 SNPs) WT* WT
46 GBM IV NO LOH (4 SNPs) NO LOH (3 SNPs) WT* WT*
47 GBM IV NO LOH (6 SNPs) NO LOH (8 SNPs) WT* TERT G228A*
48 GBM IV NO LOH (6 SNPs) NO LOH (4 SNPs) WT* TERT G228A*
49 GBM IV NO LOH (7 SNPs) NO LOH (5 SNPs) WT* TERT G228A*
50 GBM IV NO LOH (5 SNPs) NO LOH (3 SNPs) WT* TERT G228A
ODG, oligodendroglioma; AC, astrocytoma; GBM, 
glioblastoma.
The number of informative SNPs for LOH analyses is 
shown in parentheses for each sample.
*confirmed by Sanger sequencing.
Figure 3: Distribution of the molecular markers analyzed in the three histological categories (ODG, AC and GBM). 
Anaplastic ODGs and anaplastic ACs were included in the ODG and AC classes, respectively. 
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the beginning of the analysis. However, when the blood 
sample is not available, the normal counterpart could be 
dissected from FFPE sample. If blood sample or other 
normal counterparts are not available, FISH or array-CGH 
should be performed. Another possible limitation of the 
MS test compared to FISH or array-CGH is that, similar 
to STRs analysis and also to NGS approaches [28–30], it 
reveals allelic imbalances but cannot distinguish between 
chromosome deletions or amplifications. Although 1p 
and 19q duplications are also possible features of glioma, 
concurrent duplications of both chromosome regions 
are a really rare event, thus the presence of concurrent 
imbalances is almost certainly due to a codeletion of both 
chromosome arms. The 1p/19q codeletion is precisely 
detected by MS (as demonstrated by our results) and it is 
currently the only chromosome imbalance with diagnostic 
value in glioma.  However, when copy number aberrations 
are found in only one of the two chromosome arms, further 
analyses should be performed, to clarify the MS results.
In addition, the possibility of simultaneously 
genotyping a number of genetic loci allows the 
combination of all the required diagnostic analyses in one 
experiment, making MS the best choice to facilitate rapid 
diagnosis, also with limiting biological starting material. 
Indeed, using the MS test it is possible to analyze IDH 
mutations and 1p/19q status simultaneously, allowing the 
concomitant evaluation of the molecular markers deemed 
mandatory by the 2016 CNS WHO classification system. 
Considering that MS would be simple to implement 
for new hotspot mutations, we extended our MS assay to 
evaluate mutations in the TERT promoter, which are not 
yet required by WHO, but are characteristic of both ODGs 
and GBMs and have recently been determined to have 
specific prognostic value in the molecular classification 
of gliomas [8, 22, 26]; moreover, TERT is also a potential 
therapeutic target, as recently demonstrated by the results 
obtained by Imetelstat treatment on various type of 
hematological and solid tumors [18, 19, 38, 39]. 
We did not include ATRX and TP53 evaluation 
in the MS assay, since there are not hotspot mutations 
at these genes, and thus traditional sequencing or 
immunohistochemical staining would be more appropriate 
approaches for evaluation of these genes. MGMT promoter 
methylation status was also not included because analysis 
of DNA methylation requires a different MS protocol that 
cannot be combined using the genotyping approach. 
Figure 4: Spectra and electropheromgrams representative of IDH and TERT mutations. (A) Mutation in position 2 
(c.395G>A) of codon 132 of IDH1 in case 4. (B) Mutation in position G228 (c.-124C>T) of the TERT promoter in case 37. Unfilled arrows, 
position of extension primers; gray arrows, wildtype alleles (Allele 1 for IDH1 c.395 and Allele 2 for TERT c.-124); black arrows, mutant 
alleles. The allele frequencies of the wildtype and mutant alleles are indicated. Other peaks present in the spectra of IDH1_pos2 represent 
the allele signals of another SNP of the MS test. (C and D) display the results obtained by sequencing of the IDH1 in case 4 and TERT in 
case 37, respectively. Black arrows correspond to the position of the mutated allele in the sequence. 
Oncotarget57142www.impactjournals.com/oncotarget
In conclusion, the test described here represents 
a potential compromise between high-throughput 
technologies and cost- and time-effectiveness. The assay 
allows the concomitant evaluation of key markers of glioma 
characterization, comprising 1p/19q LOH status, and IDH 
and TERT mutations, conceivably in 2 working days, with 
limited cost per sample (about 80 euro per sample). The 
versatility of the MS technique makes it implementable 
with other new diagnostic markers; indeed, the MS tests 
could be also extended with the detection of other hotspot 
mutations, such as BRAF V600E, typical of few types of 
glioma, as epitheliod glioblastoma, or H3 K27M for diffuse 
midline gliomas, characteristic of pediatric patients [6].
Taken together, this approach may represent a 
step towards rapid, reliable, and cost-effective glioma 
diagnosis. The advantages and disadvantages of MS and 
the comparison with other techniques used to detect LOH 
are also detailed in Supplementary Table 2. Moreover, 
in this study, we demonstrated the feasibility of accurate 
detection of LOH using MS. Since also other chromosome 
deletions could become relevant for glioma diagnosis, 
such as 10q loss in GBMs or 9p loss in ODGs [20, 29], 
and, furthermore, deletions are also an important marker 
of genomic instability in other cancer types [40–42], the 
results using the MS approach in this study provide proof 
of principle for its future clinical application.
MATERIALS AND METHODS
Population
Fifty patients diagnosed with diffuse glioma from 
December 2013 to November 2016 at the Fondazione 
IRCCS Ca’ Granda, Ospedale Maggiore Policlinico di 
Milano were enrolled in the study on the basis of the 
availability of tumor and peripheral blood specimens. The 
study was approved by the Institutional Ethics Committee 
(Fondazione IRCCS Ca’ Granda, Ospedale Maggiore 
Policlinico no. 526/2015).
Twenty-four patients had LGGs (diffuse glioma, 
WHO grade II–III), including 12 ODGs, four anaplastic 
ODGs, five ACs, and three anaplastic ACs; the other 26 
samples were high grade gliomas (HGGs; diffuse glioma, 
WHO grade IV), termed glioblastomas (GBMs) (Table 1). 
The median age at surgery was 53 years (range, 21 to 81 
years); twenty-two patients were females and 28 males; 
forty-six patients underwent partial or total resection, 
while four patients underwent biopsy, due to the tumor 
location. This study focused on the development of a 
useful and updated molecular test for glioma diagnosis. 
Clinical aspects, such as overall survival and therapy 
response, were not considered.
Biological specimens
Tumor DNA was extracted from FFPE sections 
using a Biostic FFPE tissue DNA isolation kit (MO 
BIO Laboratories, Carlsbad, CA, USA), following the 
manufacturer’s instructions. FFPE tissue samples had 
previously been stained using hematoxylin and eosin and 
analyzed independently by two pathologists. The tumor 
cell content in all samples was at least 70%. 
DNA from PBLs was isolated using the QiAMP 
DNA Mini Kit (Qiagen, Hilden, Germany), according to 
the manufacturer’s protocol and used to test for the 1p/19q 
codeletion. 
MassARRAY procedures
Chromosome 1p/19q codeletion, and IDH and TERT 
mutations, were screened using a MassARRAY iPLEX 
platform (Agena Bioscience, San Diego, CA, USA), based 
on MALDI-TOF mass spectrometry. The results obtained 
using the MS assay were then validated by comparison 
with previous results obtained by STR genotyping or 
array-CGH.
1p/19q codeletion 
To evaluate chromosome 1p/19q codeletion in the 
tumor samples, LOH was tested for by analysis of a panel 
of 16 selected SNPs on 1p and 11 SNPs on 19q, both 
spanning the chromosome arms from their centromeric 
to their telomeric regions (Figure 5A and Supplementary 
Table 3). The homogeneous distribution of the SNPs 
along the two chromosome arms also provided the ability 
to discriminate between whole and partial chromosome 
arm imbalances. LOH assessment was performed by 
considering informative those SNPs heterozygous in PBL 
DNA, and comparing their genotypes in PBL DNA with 
those in tumor DNA. 
Using data from the Ensembl database (http://www.
ensembl.org/index.html), biallelic SNPs, with minor 
allele frequencies (MAFs) close to 0.5, were selected 
(Supplementary Table 3) since, in an ideal population, 
in accordance with Hardy-Weinberg Equilibrium, these 
SNPs would have a frequency of heterozygosity close to 
0.5. Therefore, based on MAF values, the probability of 
identifying an individual homozygous for all of the SNPs 
was verified as being very low (< 1:20,000 for 1p and 
< 1:1,700 for 19q), thus ensuring that the MS assay had 
high sensitivity for detection of LOH.
Furthermore, the percentages of samples in our 
population heterozygous for each SNP were calculated, 
and all were confirmed to be around 50% (range, 32–62%) 
(Figure 5B), reflecting the assumption inferred from the 
MAFs in the general population.
To establish when a SNP could be considered 
heterozygous based on the MS results, the raw allele 
frequencies determined using the MassARRAY Typer 
software were exploited, which represented the percentage 
of each allele detected by the instrument for each specific 
SNP in the analyzed sample. Where Allele 1 had the lower 
molecular weight (appearing on the left of the spectrum) 
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and Allele 2 the higher molecular weight (appearing on the 
right of the spectrum), allele frequencies ranged from 0 to 
1, where 0 indicates the absence, and 1 the presence, of the 
observed allele only (i.e., homozygosity or hemizygosity). 
For example, if in a given sample the frequency of Allele 1 
of SNP “x” is 0.54, the frequency of Allele 2 of this SNP will 
be 0.46; hence the sum of the allele frequencies is always 1. 
A SNP was verified as being considered heterozygous when 
the observed allele frequencies were between 0.3 and 0.7, 
as reported by the MassARRAY® Typer 3.4 Software [43]. 
Furthermore, for each heterozygous SNP the variability of 
allele frequencies was investigated by evaluating the results 
generated using heterozygous PBL samples. As depicted in 
Figure 5C, the allele frequencies of each SNP generated 
by the instrument were stable among the normal control 
heterozygous samples, with standard deviations lower 
than 10%, confirming the reliability of the MS assay (for 
an example of allele frequency see Figure 2 or Figure 4, 
the intensity of the signal of each allele is reported on the 
y axis; from the intensity of each signal the MS software 
derives the respective allele frequency).
The following equation was used to quantitatively 
define the LOH status: 
2
1
2 2
1 1
N
N
N T
N T+  
Where N1 and N2 are the frequencies of Allele 1 and 
Allele 2 found in PBL DNA and T1 and T2 are those of the 
corresponding alleles in tumor DNA. LOH was defined as 
detected when the value obtained using this formula was 
< 0.3 or > 0.7.
IDH and TERT mutations
The analysis of codons 132 of IDH1 (c.394C and 
c.395G; NP_001269316) and 172 of IDH2 (c.514A, 
c.515G, and c.516G; NP_002159), and of the c.-
124C>T (G228A) and c.-146C>T (G250A) TERT 
promoter (NP_937983) mutations, was included in the 
MS multiplexed assay. Negative and positive controls 
Figure 5: Chromosome location of SNPs, percentages of heterozygosity for each SNP, and mean allele frequencies for 
each SNP in heterozygous samples. (A) SNP chromosome locations. Chromosome images originate from the UCSC database. The 
chromosome bands in which SNPs are located are indicated. (B) Graphical representation of the percentages of heterozygous samples for 
each SNP, calculated from the results obtained from the analysis of blood DNA samples from our population. Dotted line indicates 50%. (C) 
Graphical representation of mean allele frequencies for each SNP obtained from all heterozygous PBL samples in our population. The error 
bars indicate the standard deviation from the mean allele frequencies for each SNP. Dotted lines show the range of frequencies in which a 
sample was considered heterozygous (between 30% and 70%).
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were included in each analysis; PBL DNA was used as a 
negative control while DNA samples from mutated tumors 
(previously identified by Sanger sequencing) were used as 
positive controls.
MassARRAY reactions
PCR and extension primers were designed using 
Assay Design Suite v2.0, (https://www.agenacx.com/
Logon.aspx?ReturnUrl=%2fTools), and multiplexed 
to obtain three PCR mixes. As indicated by the 
guideline procedures, a specific oligo tag sequence 
(5¢-ACGTTGGATG-) was added to the 5¢ end of each 
PCR primer to optimize the PCR reaction. Primers 
sequences are reported in Supplementary Table 3. Briefly, 
PCR amplification was conducted in 5 µl reactions 
containing 5–30 ng of DNA (depending on DNA 
availability), 100 nM PCR primers, 100 nM dNTP mix, 
PCR buffer, 25 mM MgCl2, and 5 U Taq DNA polymerase 
(Agena Bioscience, San Diego, CA, USA). The mixture 
was incubated as follows: 95°C for 2 min, 45 cycles of 
95°C for 30 sec, 56°C for 30 sec, and 72°C for 60 sec, 
with a final extension step at 72°C for 5 min. Remaining 
unincorporated dNTPs were dephosphorylated and 
inactivated by treatment with 1.7 U of shrimp alkaline 
phosphatase at 37°C for 40 min and then 85°C for 5 
min. Finally, the single base extension (SBE) reaction 
mix, including iPLEX Buffer Plus, iPLEX Termination 
Mix, Extension Primers mix, and iPLEX enzyme (Agena 
Bioscience, San Diego, CA, USA), was added to the PCR 
amplification products. The SBE reaction was carried 
out under the following conditions: 94°C for 30 sec; 40 
cycles at 94°C for 5 sec [52°C for 5 sec and 80°C for 5 sec 
(repeated five times per cycle)]; and a final extension step 
at 72°C for 3 min. Samples were spotted on a SpectroCHIP 
(Agena Bioscience, San Diego, CA, USA), and finally 
analyzed by mass spectrometry. The spectral profiles 
generated by MALDI-TOF mass spectrometry were 
analyzed using Typer v.4.0 software (Agena Bioscience, 
San Diego, CA, USA). 
Evaluation of 1p/19q LOH by STR analysis
PCRs were performed using 100 ng of DNA from 
both tumor and PBL samples, and the products were 
analyzed by capillary gel electrophoresis using Gene 
Mapper software on an ABI 3130XL system (Applied 
Biosystems, Foster City, CA, USA). Six (D1S1592, 
D1S548, D1S2694, D1S2666, D1S1612, and D1S468) 
and three (D19S412, D19S596, and D19S206) STRs 
were used to investigate the presence of deletions on 
chromosomes 1p and 19q, respectively. The genomic 
locations of the STRs and the primer sequences used to 
amplify them are provided in Supplementary Table 4. 
LOH was assessed according to the peak-height ratio, 
as previously described [44]. In brief, the peak height 
derived from each allele amplified from both tumor and 
corresponding normal DNA was compared. The formula 
(T1/T2)/(N1/N2) was applied, where T1 and T2 are the 
peak heights of the alleles detected in tumor DNA, and 
N1 and N2 are the peak heights produced from PBL 
DNA. LOH was considered present when the result of the 
calculation was < 0.50. For values > 1.00, the ratio was 
converted to 1/[(T1/T2)/(N1/N2)] and, again, LOH was 
considered present if the resulting value was < 0.50.
FISH analysis
FISH was performed in ten cases on 4-μm-thick 
sections of FFPE specimens, depending on the material 
availability. Five displayed 1p/19q LOH and five were 
without 1p/19q LOH, by MS and STR analyses. For each 
samples two slides were prepared, one for the detection 
of 1p deletion and the other one for 19q deletion. The 
sections were deparaffinized, treated with sodium 
thiocyanate and then digested with pepsin solution. 
Dual-color-probe hybridization was performed using 
ZytoLight SPEC 1p36/1q25 and 19q13/19p13 probes 
(ZytoVision, Bremerhaven, Germany). The spectrum-
green-probes label the control regions 1q25 and 19p13 of 
each chromosome, while spectrum-red-probes mark the 
targets 1p36 and 19q13. Both probes for chromosomes 1 
and 19 were denatured at 75°C for 10 minutes followed 
by an overnight hybridization at 37°C. Nuclei were 
counterstained with Leica mounting medium containing 
4’,6-diamidino-2-phenylindole (DAPI) (Leica, Wetzlar, 
Germany) and examined under a Leica DM4000B 
Fluorescence microscope (Leica, Wetzlar, Germany) 
equipped with appropriate filters (DAPI, green and red). 
Signals of 100 non-overlapping nuclei with at least 
two control/green signals were enumerated for both 
chromosomes slides.  
Interpretation of FISH images was performed 
accordingly to Ambros et al, 2001 [37]: normal pattern 
was defined by the presence of an equal number of control/
green and target/red signals (i.e. control/target ratio: 2/2, 
3/3, 4/4, etc), deletion pattern was characterized by the 
presence of at least two control/green signals but only 
one or zero target/red signals (i.e. control/target ratio: 2/1, 
2/0, 3/1, etc); finally imbalance pattern was identified by 
the presence of more than 1 target/red signal (i.e. control/
target ratio: 3/2, 4/2, 4/3, etc). 
A sample was considered positive for 1p/19q 
codeletion when more than 50% of nuclei per chromosome 
arm displayed a typical deletion pattern [37, 45, 46].
Array-CGH
In a subset of cases (two GBM and two ODGs), 
1p/19q status was also confirmed by array-CGH. 
Array-CGH analysis was performed using 180 mer 
oligonucleotide probe technology (SurePrint G3 Human 
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CGH 4 × 180K, Agilent Technologies, Santa Clara, CA, 
USA), according to the manufacturer’s instructions. Raw 
data were generated using Agilent Feature Extraction and 
analyzed using Cytogenomics 3.0.4.1, with the ADM-2 
algorithm (Agilent Technologies, Santa Clara, CA, USA). 
To improve the accuracy of the results, the Diploid Peak 
Centralization algorithm was also applied.
The aberration filter was set to detect a minimum of 
five consecutive probes/region, and the minimum absolute 
average log ratio (MAALR) was ± 0.25. A second analysis 
was run with a MAALR of ± 0.15 (again with a minimum 
number of five probes/region), to detect low level of 
mosaicism. Only copy number variants not already 
reported in the public database of genomic variants 
(http://projects.tcag.ca/variation/) were listed. Genomic 
coordinates are according to the build 37 assembly (March 
2009) of the Human Genome Reference consortium 
(GRch37/hg19).
IDH and TERT sequencing
The IDH and TERT hotspot mutations identified by 
MS were confirmed by sequencing in a subset of samples, 
based on DNA availability. The DNA regions spanning 
between the hotspot mutations in IDH1, IDH2 and TERT 
genes were amplified using the primers reported in 
Supplementary Table 4. The PCR mixture of 20 µl volume 
contained 100 ng of DNA, 1X of PCR buffer, 1.5 mM 
MgCl2, 0.2 mM of each deoxyribonucleoside triphosphate, 
0.5 μM of each primer and 0.2 units of AmpliTaq Gold DNA 
polymerase (Applied Biosystems, Foster City, CA, US). 
PCR program consisted of an initial denaturation performed 
at 95°C for 5 min, followed by 35 cycles of denaturation 
at 95°C for 20 sec, annealing for 20 sec and extension at 
72°C for 30 sec, and a final extension step at 72°C for 5 
min. PCR products were purified using the MinElute PCR 
Purification Kit (Qiagen, Hilden, Germany) and sequenced 
using the automated sequencer ABIPRISM 3130XL Genetic 
Analyzer (Applied Biosystems, Foster City, CA, US).
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